Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90β, a property that can be exploited in screens for new Hsp90 chaperone inhibitors

Gene

Volumn 302, Issue 1-2, 2003, Pages 165-170

  Piper, Peter W ^a   Panaretou, Barry ^a,b   Millson, Stefan H ^a   Trumana, Andrew ^a   Mollapour, Mehdi ^a   Pearl, Laurence H ^c   Prodromou, Chrisostomos ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anticancer agents; Chaperone inhibitors; Drug resistance; Geldanamycin; Radicicol; Saccharomyces cerevisiae

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; HEAT SHOCK PROTEIN 90; PROTEIN; PROTEIN INHIBITOR; PROTEIN STI; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; DRUG SCREENING; HUMAN; METAZOON; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; YEAST CELL;

CAENORHABDITIS; CAENORHABDITIS ELEGANS; EUKARYOTA; METAZOA; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0037413714     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(02)01102-2     Document Type: Article

References (26)

1. Adams A., Gottschling D.E., Kaiser C.A., Stearns T. Methods in Yeast Genetics. 1997;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Bagatell R., Khan O., Paine-Murrieta G., Taylor C.W., Akinaga S., Whitesell L. Destabilisation of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res. 7:2001;2076-2084.
3. Birnby D.A., Link E.M., Vowels J.J., Tian H., Colacurcio P.L., Thomas J.H. A transmembrane guanylyl cyclase (DAF-11) and Hsp90 (DAF-21) regulate a common set of chemosensory behaviors in Caenorhabditis elegans. Genetics. 155:2000;85-104.
4. Borkovich K.A., Farrelly F.W., Finkelstein D.B., Taulien J., Lindquist S. Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol. Cell. Biol. 9:1989;3919-3930.
5. Brachmann C.B., Davies A., Cost G.J., Caputo E., Li J., Hieter P., Boeke J.D. Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast. 14:1997;115-132.
6. Cutforth T., Rubin G.M. Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila. Cell. 77:1994;1027-1036.
7. Kwon H.J., Yoshida M., Fukui Y., Horinouchi S., Beppu T. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52:1992;6926-6930.
8. Liu X.D., Morano K.A., Thiele D.J. The yeast Hsp110 family member, Sse1, is an Hsp90 cochaperone. J. Biol. Chem. 274:1999;26654-26660.
9. Louvion J.F., Warth R., Picard D. Two eukaryote-specific regions of Hsp82 are dispensable for its viability and signal transduction functions in yeast. Proc. Natl. Acad. Sci. USA. 93:1996;13937-13942.
10. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2:2002;3-24.
11. McLaughlin S.H., Smith H.W., Jackson S.E. Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J. Mol. Biol. 315:2002;787-798.
12. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8:2002;S55-S61.
13. Panaretou B., Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17:1998;4829-4836.
14. Panaretou B., Sinclair K., Prodromou C., Johal J., Pearl L., Piper P.W. The Hsp90 of Candida albicans can confer Hsp90 functions in Saccharomyces cerevisiae: a potential model for the processes that generate immunogenic fragments of this molecular chaperone in C. albicans infections. Microbiology. 145:1999;3455-3463.
15. Picard D., Khursheed B., Garabedian M.J., Fortin M.G., Lindquist S., Yamamoto K.R. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature. 348:1990;166-168.
16. Piper P.W. The Hsp90 chaperone as a promising drug target. Curr. Opin. Investig. Drugs. 2:2001;1606-1610.
17. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Identification and structural characterisation of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 90:1997;65-75.
18. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
19. Schneider C., Sepp-Lorenzino L., Nimmesgern E., Ouerfelli O., Danishefsky S., Rosen N., Hartl F.U. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA. 93:1996;14536-14541.
20. Schulte T.W., Blagosklonny M.V., Ingui C., Neckers L. Disruption of the raf-1-Hsp90 molecular complex results in destabilisation of raf-1 and the loss of raf-1-ras association. J. Biol. Chem. 270:1995;24585-24588.
21. Schulte T.W., Akinaga S., Murakata T., Agatsuma T., Sugimoto S., Nakano H., Lee Y.S., Simen B.B., Argon Y., Felts S., Toft D.O., Neckers L.M., Sharma S.V. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol. Endocrinol. 13:1999;1435-1448.
22. Smith D.F., Whitesell L., Katsanis K. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 50:1998;493-514.
23. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 89:1997;239-250.
24. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Prelinical pharmacological evaluation of geldanamycin as an antitumour agent. Cancer Chemother. Pharmacol. 36:1995;305-315.
25. Uehara Y., Hori M., Takeuchi T., Umezawa H. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol. 6:1986;2198-2206.
26. Whitesell L., Sutphin P., An W.G., Schulte T., Blagosklonny M.V., Neckers L. Geldanamycin-stimulated destabilisation of mutated p53 is mediated by the proteasome in vivo. Oncogene. 14:1997;2809-2816.